全文获取类型
收费全文 | 23393篇 |
免费 | 825篇 |
国内免费 | 167篇 |
专业分类
耳鼻咽喉 | 548篇 |
儿科学 | 2054篇 |
妇产科学 | 238篇 |
基础医学 | 937篇 |
口腔科学 | 262篇 |
临床医学 | 6372篇 |
内科学 | 2059篇 |
皮肤病学 | 146篇 |
神经病学 | 1078篇 |
特种医学 | 479篇 |
外科学 | 3474篇 |
综合类 | 2125篇 |
预防医学 | 2240篇 |
眼科学 | 148篇 |
药学 | 1434篇 |
17篇 | |
中国医学 | 309篇 |
肿瘤学 | 465篇 |
出版年
2024年 | 29篇 |
2023年 | 746篇 |
2022年 | 1279篇 |
2021年 | 1521篇 |
2020年 | 1192篇 |
2019年 | 1519篇 |
2018年 | 1433篇 |
2017年 | 861篇 |
2016年 | 777篇 |
2015年 | 780篇 |
2014年 | 1983篇 |
2013年 | 1705篇 |
2012年 | 1437篇 |
2011年 | 1619篇 |
2010年 | 1147篇 |
2009年 | 992篇 |
2008年 | 855篇 |
2007年 | 638篇 |
2006年 | 546篇 |
2005年 | 443篇 |
2004年 | 312篇 |
2003年 | 192篇 |
2002年 | 144篇 |
2001年 | 157篇 |
2000年 | 155篇 |
1999年 | 136篇 |
1998年 | 132篇 |
1997年 | 109篇 |
1996年 | 100篇 |
1995年 | 85篇 |
1994年 | 73篇 |
1993年 | 55篇 |
1992年 | 48篇 |
1991年 | 44篇 |
1990年 | 43篇 |
1989年 | 43篇 |
1988年 | 37篇 |
1985年 | 109篇 |
1984年 | 124篇 |
1983年 | 86篇 |
1982年 | 100篇 |
1981年 | 87篇 |
1980年 | 82篇 |
1979年 | 70篇 |
1978年 | 50篇 |
1977年 | 44篇 |
1976年 | 69篇 |
1975年 | 42篇 |
1974年 | 51篇 |
1973年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
目的 根据乳腺癌内分泌治疗患者的症状特征,编制适用于我国乳腺癌内分泌治疗患者的症状评估量表,并检验其信效度。方法 在文献回顾及参照现有症状评估量表的基础上编制量表初始条目池;通过2轮德尔菲专家函询,形成初始版量表;通过对11例患者的认知性访谈,对量表条目进一步修订,形成临床测试版量表。便利选取2020年7月—9月在浙江省某三级甲等肿瘤医院门诊或住院的325例乳腺癌内分泌治疗患者进行问卷调查,检验量表信效度。 结果 形成的最终版乳腺癌内分泌治疗患者症状评估量表包括33个条目,探索性因子分析提取7个公因子,累计方差贡献率为68.76%;各条目内容效度指数为0.78~1.00,量表内容效度指数为0.91;内在相关性检验结果显示,量表各维度与总量表相关系数为0.58~0.79(P<0.05);维度间相关系数为0.26~0.52(P<0.05);总量表Cronbach’s α系数为0.94,重测信度为0.95,折半信度为0.84。结论 编制的乳腺癌内分泌治疗患者症状评估量表具有良好的信效度,适用于相关人群的症状测评。 相似文献
3.
《Journal of infection and chemotherapy》2022,28(4):548-553
IntroductionCOVID-19 patients have been reported to have digestive symptoms with poor outcome. Ivermectin, an antiparasitic drug, has been used in COVID-19 patients. The objective of this study was to evaluate whether ivermectin has effects on gastrointestinal complications and ventilator-free days in ventilated patients with COVID-19.MethodsCOVID-19 patients who were mechanically ventilated in the ICU were included in this study. The ventilated patients who received ivermectin within 3 days after admission were assigned to the Ivermectin group, and the others were assigned to the Control group. Patients in the Ivermectin group received ivermectin 200 μg/kg via nasal tube. The incidence of gastrointestinal complications and ventilator-free days within 4 weeks from admission were evaluated as clinical outcomes using a propensity score with the inverse probability weighting method.ResultsWe included 88 patients in this study, of whom 39 patients were classified into the Ivermectin group, and 49 patients were classified into the Control group. The hazard ratio for gastrointestinal complications in the Ivermectin group as compared with the Control group was 0.221 (95% confidence interval [CI], 0.057 to 0.855; p = 0.029) in a Cox proportional-hazard regression model. The odds ratio for ventilator-free days as compared with the Control group was 1.920 (95% CI, 1.076 to 3.425; p = 0.027) in a proportional odds logistic regression model.ConclusionsIvermectin improved gastrointestinal complications and the number of ventilator-free days in severe COVID-19 patients undergoing mechanical ventilation. Prevention of gastrointestinal symptoms by SARS-Cov-2 might be associated with COVID-19 outcome. 相似文献
4.
5.
6.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
7.
8.
9.
10.
Ehsan Zarei Elmira Madarshahian Adeleh Nikkhah Soheila Khodakarim 《Journal of tissue viability》2019,28(2):70-74